Christine Cvijic
Finanzdirektor/CFO bei Neurogene, Inc.
Vermögen: 2 Mio $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Rachel McMinn | M | 51 |
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 6 Jahre |
| Christine Mikail, | - | - |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 9 Jahre |
| Cory Freedland | M | 48 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 1 Jahre |
| Robert Baffi | M | 68 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 4 Jahre |
| R. Woods | M | 56 | 1 Jahre | |
| Arvind Sreedharan | M | - |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | - |
| Sarah Noonberg | M | 56 | 1 Jahre | |
| Rohan Palekar | M | 58 | 1 Jahre | |
| Julie Jordan | M | - | - | |
| Katherine Betz-Doherty | F | - | 6 Jahre | |
| Germo Gericke | M | - | 6 Jahre | |
| Jessica Toepfer | F | - | 6 Jahre | |
| Gino Santini | M | 67 |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 16 Jahre |
| Frédéric Collet | M | - | 6 Jahre | |
| Andrew E. Mulberg | M | - | - | |
| Sukumar Nagendran | M | 58 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 5 Jahre |
| Ricardo Jimenez | M | - | - | |
| Donna Cochener-Metcalfe | F | 49 | - | |
| William Chin | M | 76 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 16 Jahre |
| Stuart Cobb | M | 54 | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Francois Nader | M | 67 | 10 Jahre | |
| John Johnson | M | 66 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 3 Jahre |
| Stefano Buono | M | 57 | 16 Jahre | |
| Louis Ferrari | M | 71 | 2 Jahre | |
| Kenneth Zuerblis | M | 64 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 3 Jahre |
| Richard Crowley | M | 67 | - | |
| David Norton | M | 72 | 3 Jahre | |
| Vivek Ramaswamy | M | 38 | 3 Jahre | |
| Paul R. Hamelin | M | 69 | 5 Jahre | |
| Gérard Ber | M | 66 | 16 Jahre | |
| Heinz Christoph Mäusli | M | 61 | 15 Jahre | |
| John E. Celentano | M | 64 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | - |
| Ilise Lombardo | M | - | 4 Jahre | |
| Alan Roemer | M | 54 | - | |
| Atul Pande | M | 69 | 8 Jahre | |
| Shankar Ramaswamy | M | - | 4 Jahre | |
| Brendan P. Rae | M | - | 1 Jahre | |
| Eric Floyd | M | 62 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | - |
| Joseph I. DePinto | M | 57 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 4 Jahre |
| Marianne Romeo | F | 56 | - | |
| Kapil Dhingra | M | 64 | 4 Jahre | |
| Edward H. Stratemeier | M | 75 | 5 Jahre | |
| Berndt A. E. Modig | M | 65 | 8 Jahre | |
| Stephen Davies | M | - | - | |
| William F. Owen | M | 68 | 2 Jahre | |
| Susanne Antonie Schaffert | M | 57 | 1 Jahre | |
| Steven Gannon | M | 62 | 4 Jahre | |
| Eric Rowinsky | M | 67 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 4 Jahre |
| Pedro Granadillo | M | 77 | 5 Jahre | |
| Gregory Mark Weinhoff | M | 53 | 4 Jahre | |
| Michael Bonney | M | 65 | 10 Jahre | |
| Lawrence Olanoff | M | 72 | 2 Jahre | |
| Roger Garceau | M | 70 | 7 Jahre | |
| Kenneth Bahrt | M | 71 | 4 Jahre | |
| Colin Broom | M | 68 | 6 Jahre | |
| Joan C. Winterbottom | F | 67 | 1 Jahre | |
| Bruce Yeager | M | - | - | |
| Kevin Peacock | M | - | - | |
| Stephen Smolinski | M | 59 | 2 Jahre | |
| Ramona M. Lloyd | M | - |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 1 Jahre |
| Laura Mattlin | F | - |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 1 Jahre |
| David Veitch | M | 59 | 1 Jahre | |
| Michael P. Bailey | M | 58 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 9 Jahre |
| Ilan Oren | M | 40 | 2 Jahre | |
| Gary Pisano | M | 62 | 1 Jahre | |
| Elizabeth Yamashita | F | - | 1 Jahre | |
| Michael Adasczik | M | 50 | 3 Jahre | |
| Patrik Florencio | M | - | 1 Jahre | |
| Steven Paul | M | 73 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | - |
| Marcio Souza | M | 45 | 2 Jahre | |
| Luke Beshar | M | 65 | 8 Jahre | |
| Vishal Kapoor | M | 48 | 1 Jahre | |
| Niva Almaula | M | - | 3 Jahre | |
| Marsha Wolfson | M | - | - | |
| Charles Woler | M | 74 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 2 Jahre |
| David Sidransky | M | 64 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 4 Jahre |
| Paul Firuta | M | 58 | 1 Jahre | |
| Peter S. Liebert | M | 88 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 2 Jahre |
| Pierre Legault | M | 63 | 1 Jahre | |
| Jules Haimovitz | M | 73 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 1 Jahre |
| Andrew Bonfield | M | 61 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 1 Jahre |
| Alexander Denner | M | 54 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 2 Jahre |
| Richard Mulligan | M | 69 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 2 Jahre |
| Margaret Dalesandro | M | 77 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 7 Jahre |
| Robin D. Friedman | F | - | 1 Jahre | |
| John Sørensen Haurum | M | 61 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 2 Jahre |
| Andrew Powell | M | 66 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 1 Jahre |
| Thomas F. Deuel | M | 89 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 1 Jahre |
| Bryce D. Carmine | M | 72 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | - |
| Gregory Mayes | M | 55 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 6 Jahre |
| Robert L. Crotty | M | 50 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 3 Jahre |
| Srdjan Stankovic | M | 67 |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | 4 Jahre |
| Carl Icahn | M | 88 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 2 Jahre |
| Derica Rice | M | 59 |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | - |
| Glenn R. Melrose | M | 68 | 2 Jahre | |
| Claudio Costamagna | M | 68 | 6 Jahre | |
| Leah Neufeld | F | 51 | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 77 | 79,38% |
| Frankreich | 14 | 14,43% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Christine Cvijic
- Persönliches Netzwerk
